皮质类固醇治疗免疫相关不良事件与检查点抑制剂疗效:六项临床试验分析
该研究对六项国际II/III期注册试验中接受抗PD-1+抗CTLA-4治疗的患者数据进行事后分析,评估因治疗相关不良事件使用全身免疫抑制与生存的关联。结果显示较高的皮质类固醇峰值剂量与较差的无进展生存和总生存相关,而累积剂量与生存无关。作者认为这些数据支持重新考虑irAE管理方法,尽可能起始使用较低皮质类固醇剂量。
要点
- 在1959例接受抗PD-1+抗CTLA-4治疗的患者中,834例因治疗相关不良事件接受免疫抑制治疗被纳入分析。
- 皮质类固醇峰值剂量较高与较差的无进展生存相关:1 vs 0.5 mg/kg泼尼松龙的校正HR为1.15(95%CI 1.02-1.29),2 vs 0.5 mg/kg为1.43(95%CI 1.05-1.96)。
- 皮质类固醇峰值剂量较高与较差的总生存相关:1 vs 0.5 mg/kg的校正HR为1.21(95%CI 1.06-1.39),2 vs 0.5 mg/kg为1.66(95%CI 1.17-2.37);累积剂量与生存无关。
核心结论
- 较高的皮质类固醇峰值剂量与治疗相关不良事件患者跨瘤种更差的生存相关,而累积剂量无关。
- 接受二线免疫抑制剂的患者太少,无法确认或排除其与生存的关联。
- 这些数据支持重新考虑irAE管理方法,尽可能起始使用较低皮质类固醇剂量。
研究设计与样本
- 对六项国际II/III期注册试验(CheckMate-067、-142、-214、-648、-743和-9LA)抗PD-1+抗CTLA-4治疗臂的个体患者数据进行事后分析。
- 在1959例接受抗PD-1+抗CTLA-4治疗的患者中,834例因治疗相关不良事件接受免疫抑制治疗的患者被纳入分析。
- 采用多水平Cox回归评估皮质类固醇峰值剂量、累积剂量及二线免疫抑制剂使用与总生存和无进展生存的关联,并校正年龄和性别。
主要发现
- 834例纳入患者中,832例(100%)接受皮质类固醇,81例(10%)接受二线免疫抑制剂。
- 皮质类固醇峰值剂量较高与较差的无进展生存相关:1 vs 0.5 mg/kg泼尼松龙的校正HR为1.15(95%CI 1.02-1.29),2 vs 0.5 mg/kg为1.43(95%CI 1.05-1.96)。
- 皮质类固醇峰值剂量较高与较差的总生存相关:1 vs 0.5 mg/kg的校正HR为1.21(95%CI 1.06-1.39),2 vs 0.5 mg/kg为1.66(95%CI 1.17-2.37)。
- 皮质类固醇累积剂量与生存无关。
- 二线免疫抑制剂使用的校正HR为无进展生存1.23(95%CI 0.90-1.68),总生存1.25(95%CI 0.88-1.77)。
临床怎么用
- 作者认为这些数据支持重新考虑irAE管理方法,尽可能起始使用较低皮质类固醇剂量。
局限性
- 接受二线免疫抑制剂的患者太少,无法确认或排除其与生存的关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Retrospective studies suggest that immunosuppressive treatment of immune-related adverse events (irAEs) impairs survival in patients with melanoma who received immune checkpoint inhibitors. Here, we study this association across tumor types using data from six international phase II/III registrational trials. METHODS: A post hoc analysis was performed on individual patient data from the anti-programmed cell death-1 (anti-PD-1) + anti-cytotoxic T lymphocyte-associated protein-4 (anti-CTLA-4) treatment arms of six clinical trials (CheckMate-067, -142, -214, -648, -743, and -9LA). Among patients who received systemic immunosuppression for treatment-related adverse events (trAEs), associations of peak and cumulative corticosteroid dose, and use of second-line immunosuppression with overall survival (OS) and progression-free survival (PFS) were assessed using multilevel Cox regression with adjustment for age and sex. RESULTS: Of the 1,959 patients who received anti-PD-1 + anti-CTLA-4 therapy, 834 patients who were treated with immunosuppression for trAEs were included. Eight hundred and thirty-two patients (100%) received corticosteroids and 81 patients (10%) received second-line immunosuppressants. High corticosteroid peak dose was associated with worse PFS: adjusted hazard ratio (HRadj), 1.15 (95% CI, 1.02 to 1.29) for 1 versus 0.5 mg/kg prednisolone and HRadj, 1.43 (95% CI, 1.05 to 1.96) for 2 versus 0.5 mg/kg. Similar effects were observed for OS: HRadj, 1.21 (95% CI, 1.06 to 1.39) and HRadj, 1.66 (95% CI, 1.17 to 2.37) for 1 and 2 versus 0.5 mg/kg, respectively. Cumulative corticosteroid dose was not associated with survival. HRadj of use of second-line immunosuppression was 1.23 (95% CI, 0.90 to 1.68) for PFS and 1.25 (95% CI, 0.88 to 1.77) for OS. CONCLUSION: Higher corticosteroid peak dose for trAEs is associated with worse survival across tumor types, while cumulative dose is not. Too few patients received second-line immunosuppressants to confirm or reject an association with survival. These data argue for a reconsideration of irAE management approaches, starting with lower corticosteroid dose whenever feasible.
引用
- Verheijden RJ, de Groot JS, Fabriek BO, et al. Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials. J Clin Oncol. 2024. PMID: 39110922. doi:10.1200/JCO.24.00191
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。